Interdisciplinary Centre for Clinical Research, University Hospital Erlangen, FAU-Erlangen-Nuremberg, Erlangen, Germany.
Department of Experimental Medicine-I and Comprehensive Cancer Center Erlangen-EMN, Friedrich Alexander University of Erlangen-Nuremberg, Erlangen, Germany.
Trends Cancer. 2020 Nov;6(11):942-950. doi: 10.1016/j.trecan.2020.06.005. Epub 2020 Jul 15.
Epithelial-to-mesenchymal transition (EMT) determines the most lethal features of cancer, metastasis formation and chemoresistance, and therefore represents an attractive target in oncology. However, direct targeting of EMT effector molecules is, in most cases, pharmacologically challenging. Since emerging research has highlighted the distinct metabolic circuits involved in EMT, we propose the use of metabolism-specific inhibitors, FDA approved or under clinical trials, as a drug repurposing approach to target EMT in cancer. Metabolism-inhibiting drugs could be coupled with standard chemo- or immunotherapy to combat EMT-driven resistant and aggressive cancers.
上皮-间充质转化 (EMT) 决定了癌症最致命的特征，如转移形成和化疗耐药性，因此它是肿瘤学中的一个有吸引力的靶点。然而，在大多数情况下，直接靶向 EMT 效应分子在药理学上具有挑战性。由于新兴的研究强调了 EMT 中涉及的独特代谢途径，我们建议使用代谢特异性抑制剂（FDA 批准或正在临床试验中）作为药物再利用方法，以针对癌症中的 EMT。代谢抑制药物可以与标准的化疗或免疫疗法联合使用，以对抗 EMT 驱动的耐药性和侵袭性癌症。
